Journals / Tüberküloz ve Toraks / 2011 / Cilt: 59 - Sayı: 1

Plevral efüzyonların ayırıcı tanısında serum ve plevral sıvı N-Terminal-Pro-B-Tip natriüretik peptid konsantrasyonunun yeri

Serum and pleural fluid N-Terminal-Pro-B-Type natriuretic peptide concentrations in the differential diagnosis of pleural effusions

Pages
1–7
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We suggest that measurement of pleural fluid NT-proBNP is a smart approach and pleural fluid NTproBNP can reflect cardiac origin of effusions better than serum NT-proBNP and Light’s criteria

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Currently, new biomarkers like N-Terminal-Pro-B-Type natriuretic peptide (NT-proBNP) have been used in the differential diagnosis of pleural effusions.
📊
Key Findings & Data:Thirtyeight pleural effusions were exudative and, 7 were transudative according to the Light’s criteria.
💡
Conclusion & Impact:We suggest that measurement of pleural fluid NT-proBNP is a smart approach and pleural fluid NTproBNP can reflect cardiac origin of effusions better than serum NT-proBNP and Light’s criteria
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Currently, new biomarkers like N-Terminal-Pro-B-Type natriuretic peptide (NT-proBNP) have been used in the differential diagnosis of pleural effusions. In our study, we aimed to investigate the diagnostic value of NT-proBNP, especially in cardiac originated pleural effusions. Forty-five patients with pleural effusions were included in the study. NT-proBNP levels and biochemical markers involved in the Light’s criteria were analyzed in pleural fluid and serums of the patients. Pleural fluid culture, AFB smear, cytology were performed where they were indicated according to the clinical evaluation. In patients, to whom cardiac pathology was considered to be; cardiological evaluation and echocardiography were also done. Thirtyeight pleural effusions were exudative and, 7 were transudative according to the Light’s criteria. Final diagnosis were malignant effusion in 13, infection (tuberculosis/pneumonia) in 10, congestive heart failure in 21, and other conditions related with pleural effusion in 1 of the patients. Median (25th to 75th percentiles) NT-proBNP levels of serum and pleural fluid due to congestive heart failure (CHF) were 4747 pg/mL (931-15754) and 4827 pg/mL (1290-12.430) while median NTproBNP levels of serum and pleural fluid related with non-cardiac reasons were 183 pg/mL (138-444) and 245 pg/mL (187- 556) respectively. NT-proBNP levels of serum and pleural fluid were significantly high in CHF (p< 0.001 for both). When four groups were compared serum and pleural fluid NT-proBNP levels were highest in the CHF group which was followed by malignancy, infection and others (p< 0.001 for both). Fourteen of 21 patients who were accepted to have congestive heart failure as the final diagnosis by a cardiological evaluation had an exudative pleural fluid according to the Light’s criteria. Serum and pleural fluid NT-proBNP levels were higher in transudates and this reached statistically significance for pleural fluid (p= 0.009). We suggest that measurement of pleural fluid NT-proBNP is a smart approach and pleural fluid NTproBNP can reflect cardiac origin of effusions better than serum NT-proBNP and Light’s criteria

Özet

Son yıllarda, plevral efüzyonların ayırıcı tanısında N-Terminal-Pro-B-Tip natriüretik peptid (NT-proBNP) gibi yeni belirteçlerin kullanımı gündemdedir. Çalışmamızda, NT-proBNP’nin özellikle kardiyak kaynaklı plevral efüzyonlarda tanısal değerini araştırmayı amaçladık. Plevral efüzyonu olan 45 hasta çalışmaya dahil edildi. Hastaların serum ve plevral efüzyonlarında NT-proBNP düzeyleri ve Light kriterlerinde yer alan biyokimyasal belirteçler analiz edildi. Klinik değerlendirmeye göre, gereken durumlarda plevral sıvının kültürü, ARB direkt muayenesi ve sitolojik tetkiki yapıldı. Kardiyak patoloji düşünülen hastalarda, kardiyolojik değerlendirme ve ekokardiyografi de yapıldı. Light kriterlerine göre plevral efüzyonların 38’i eksüda, yedisi transüdaydı. Hastaların 13’ünde son tanı malign efüzyon, 10’unda infeksiyon (tüberküloz/pnömoni), 21’inde konjestif kalp yetmezliği, birinde ise plevral efüzyonla ilgili diğer hastalıktı. Konjestif kalp yetmezliği ile ilişkili plevral sıvılarda, medyan (25-75. çeyrekler) NT-proBNP düzeyleri serumda 4747 pg/mL (931-15754), plevral sıvıda ise 4827 pg/mL (1290-12430) idi. Kardiyak olmayan nedenlere bağlı plevral sıvılarda ise bu düzeyler serumda 183 pg/mL (138-444), plevral sıvıda 245 pg/mL (187-556) olarak saptandı. Konjestif kalp yetmezliği olan hastalarda serum ve plevral sıvı NT-proBNP düzeyleri anlamlı olarak yüksekti (her ikisi için p< 0.001). Son tanılarına göre dört grup karşılaştırıldığında serum ve plevral sıvı NT-proBNP düzeyleri en yüksek konjestif kalp yetmezliğinde gözlendi, bunu malignite, infeksiyon ve diğerleri izlemekteydi (her ikisi için p< 0.001). Kardiyolojik değerlendirme ile konjestif kalp yetmezliği kabul edilen 21 hastanın 14’ünde Light kriterlerine göre eksüda mevcuttu. Transüdalarda serum ve plevral sıvı NT-proBNP düzeyleri istatistiksel anlamlı olarak yüksekti (p= 0.009). Plevral sıvı NT-proBNP düzeylerinin ölçümü iyi bir yaklaşımdır ve plevral sıvı NT-proBNP düzeyleri kardiyak kaynaklı sıvıları Light kriterleri ve serum NT-proBNP düzeylerine göre daha iyi yansıtır.

🔖

Cite This Article

ÖZGEN, A. A., BAYTURAN, Ö., YAMAN, N., ŞAKAR, A. C., ÇELİK, P., YORGANCIOĞLU, A., TANELİ, F. (2022). Plevral efüzyonların ayırıcı tanısında serum ve plevral sıvı N-Terminal-Pro-B-Tip natriüretik peptid konsantrasyonunun yeri. Tüberküloz ve Toraks, Cilt: 59 - Sayı: 1, 1–7. https://ajindex.com/articles/619050

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Light RW. Clinical practice. Pleural effusion. N Engl J Med 2002; 346: 1971-7
  2. Gegenhuber A, Mueller T, Dieplinger B, et al. Serum B-type natriuretic peptide in patients with pleural effusions: preliminary observations. Chest 2005; 128: 1003-9
  3. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest 1997; 111: 970-80
  4. Porcel JM, Peña JM, Vicente de Vera C, Esquerda A. Reappraisal of the standard method (Light’s criteria) for identifying pleural exudates. Med Clin (Barc) 2006; 126: 211-3
  5. Kolditz M, Halank M, Schiemanck CS, et al. High diagnostic accuracy of NT-pro BNP for cardiac origin of pleural effusions. Eur Respir J 2006; 28: 144-50
  6. Gotsman I, Fridlender Z, Meirovitz A, et al. The evaluation of pleural effusions in patients with heart failure. Am J Med 2001; 111: 375-8
  7. Chakko SC, Caldwell SH, Sforza PP. Treatment of congestive heart failure. Its effect on pleural fluid chemistry. Chest 1989; 95: 798-802
  8. Martinez Rumayor A, Richards AM, Burnett JC, Januzzi JL. Biology of the natriuretic peptides. Am J Cardiol 2008; 101(Suppl): 3A-8A
  9. Mukoyama M, Nakao K, Saito Y, et al. Human brain natriuretic peptide, a novel cardiac hormone. Lancet 1990; 335: 801-2
  10. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4: 72-80
  11. Hobbs FD, Davis RC, Roalfe AK, et al. Reliability of N-terminal pro-brain natriuretic peptide assay in the diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002; 324: 1498
  12. Steq PG, Joubin L, McCord J, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005; 128: 21-9
  13. Hunt SA, Baker DW, Chin MH, et al. American College of Cardiology/ American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-13
  14. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur He